Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: The molecular basis for PML-RARalpha- mediated leukemogenesis is complex involving both the repression of numerous potential target genes and critical 'off promoter' functional activity of this fusion protein. The acute promyelocytic leukemia specific repressive chromatin marks related to PML-RARalpha activity may be present in other myeloid leukemias as well. This suggests alternative approaches for treating myeloid leukemia involving therapeutic agents that inhibit heterochromatin formation and enhance transcriptional activity. All-trans retinoic acid or related compounds may also play a significant role in enhancing hematopoietic stem cell self-renewal as well as the production and differentiation of regulatory T cells.
|
Authors | Steven J Collins |
Journal | Current opinion in hematology
(Curr Opin Hematol)
Vol. 15
Issue 4
Pg. 346-51
(Jul 2008)
ISSN: 1531-7048 [Electronic] United States |
PMID | 18536573
(Publication Type: Journal Article, Review)
|
Chemical References |
- Receptors, Retinoic Acid
- Tretinoin
|
Topics |
- Animals
- Cell Differentiation
(drug effects)
- Hematopoiesis
- Humans
- Leukemia, Myeloid
(drug therapy, etiology)
- Leukemia, Promyelocytic, Acute
(drug therapy, etiology)
- Receptors, Retinoic Acid
- Tretinoin
(pharmacology, therapeutic use)
|